Croissance des activités réalisées aux laboratoires d’Évry Plan de restructuration et de réduction des coûts lié à l’arrêt des prestations pour le GCS SeqOIA en février Résilience de la...
The discontinuation of services for the SeqOIA platform mechanically led to a 20% reduction in revenues in the first half of the year. Adjusted for this base effect, growth was 6% over the...
Increase in services provided in 2023 by all sequencing platforms, excluding COVID-related activities Positive EBITDA for the third year running, despite inflation impacting reagent costs SeqOIA...
Significant reduction of COVID-19 related activities Growth of all other lines of business Cash totaling €2.9m on Dec 31st, 2023 Laboratory in Évry accredited by the College of American...
Résilience de la rentabilité malgré le contexte inflationniste Croissance des activités aux laboratoires d’Évry Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME...
Baisse de l’activité de la plateforme de séquençage en microbiologie après une forte contribution enregistrée au 1er semestre 2022 dans le cadre de la pandémie de Covid-19. Retraitée de cet...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 0.952380952381 | 0.525 | 0.57 | 0.5 | 6532 | 0.5343195 | DE |
4 | 0.06 | 12.7659574468 | 0.47 | 0.58 | 0.434 | 7868 | 0.49559753 | DE |
12 | -0.005 | -0.934579439252 | 0.535 | 0.67 | 0.434 | 6499 | 0.51045727 | DE |
26 | -0.04 | -7.01754385965 | 0.57 | 0.705 | 0.434 | 4075 | 0.53236089 | DE |
52 | -0.342 | -39.2201834862 | 0.872 | 0.93 | 0.434 | 5097 | 0.65805923 | DE |
156 | -0.56 | -51.376146789 | 1.09 | 2.04 | 0.434 | 5558 | 1.16759556 | DE |
260 | -0.412 | -43.7367303609 | 0.942 | 2.67 | 0.434 | 32511 | 1.70348267 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관